Home » Stocks » Merck

Merck & Co., Inc. (MRK)

Stock Price: $78.78 USD 0.66 (0.84%)
Updated Jul 2, 2020 4:02 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 198.85B
Revenue (ttm) 48.08B
Net Income (ttm) 10.15B
Shares Out 2.52B
EPS (ttm) 3.95
PE Ratio 19.94
Forward PE 14.47
Dividend $2.44
Dividend Yield 3.10%

Stock Quote

Trading Day Jul 2, 2020
Last Price $78.78
Previous Close $78.12
Change ($) 0.66
Change (%) 0.84%
Day's Open 78.57
Day's Range 78.22 - 79.31
Day's Volume 6,515,116
52-Week Range 65.25 - 92.64

More Stats

Market Cap 198.85B
Enterprise Value 219.41B
Earnings Date (est) Jul 31, 2020
Ex-Dividend Date Jun 12, 2020
Shares Outstanding 2.52B
Float 2.52B
EPS (basic) 3.98
EPS (diluted) 3.95
FCF / Share 3.53
Dividend $2.44
Dividend Yield 3.10%
Earnings Yield 5.01%
FCF Yield 4.50%
Payout Ratio 58.30%
Shares Short 15.81M
Short Ratio 1.49
Short % of Float 0.63%
Beta 0.50
PE Ratio 19.94
Forward PE 14.47
P/FCF Ratio 22.23
PS Ratio 4.14
PB Ratio 7.39
Revenue 48.08B
Operating Income 12.26B
Net Income 10.15B
Free Cash Flow 8.95B
Net Cash -20.57B
Net Cash / Share -8.15
Gross Margin 70.06%
Operating Margin 25.49%
Profit Margin 21.10%
FCF Margin 18.61%
ROA 11.76%
ROE 37.55%
ROIC 25.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 12
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$92.60*
(17.54% upside)
Low
84.0
Current: 78.78
High
107.0
Target: 92.60
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue46,84042,29440,12239,80739,49842,23744,03347,26748,04745,987
Revenue Growth10.75%5.41%0.79%0.78%-6.48%-4.08%-6.84%-1.62%4.48%-
Gross Profit32,72828,78527,21025,77724,56425,46927,07930,82131,17627,591
Operating Income11,6038,2996,0214,8486,9285,6705,9569,2137,6702,370
Net Income9,8436,2202,3943,9204,44211,9204,4046,1686,272861
Shares Outstanding2,5462,6002,7242,7572,7942,8512,9223,0403,0483,081
Earnings Per Share3.812.320.871.411.564.071.472.002.020.28
EPS Growth64.22%166.67%-38.3%-9.62%-61.67%176.87%-26.5%-0.99%621.43%-
Dividend Per Share2.261.991.891.851.811.771.731.691.561.52
Dividend Growth13.57%5.29%2.16%2.21%2.26%2.31%2.37%8.33%2.63%-
Operating Cash Flow13,44010,9226,45110,37612,5387,98911,65410,02212,38310,822
Capital Expenditures-3,473-2,615-1,888-1,614-1,283-1,317-1,548-1,954-1,723-1,678
Free Cash Flow9,9678,3074,5638,76211,2556,67210,1068,06810,6609,144
Cash & Equivalents10,4508,8648,49814,34113,42715,71917,48616,14114,97212,201
Total Debt26,34625,11424,41024,84226,41221,40325,06020,56917,51517,882
Net Cash / Debt-15,896-16,250-15,912-10,501-12,985-5,684-7,574-4,428-2,543-5,681
Assets84,39782,63787,87295,377101,67798,167105,645106,132105,128105,781
Liabilities58,39655,75553,30355,06956,91049,37653,31950,66948,18548,976
Book Value25,90726,70134,33640,08844,67648,64749,76553,02054,51754,376
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Merck & Co., Inc.
Country United States
Employees 71,000
CEO Kenneth C. Frazier

Stock Information

Ticker Symbol MRK
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: MRK

Description

Merck & Co., Inc. provides healthcare solutions worldwide. It operates through Pharmaceutical and Animal Health segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products; and dog, cat, and horse vaccines. The company serves drug wholesalers and retailers, hospitals, government agencies, managed health care providers, physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; PeptiDream Inc.; Shanghai Junshi Biosciences Co., Ltd.; Targovax ASA; and Linnaeus Therapeutics, Inc. It also has strategic research collaboration and license agreement with Yumanity Therapeutics. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.